Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- 9 June 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 55 (5), 1396-1405
- https://doi.org/10.1007/s10620-009-0839-8
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)Cancer, 2007
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate CancerClinical Cancer Research, 2007
- A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced MalignancyClinical Cancer Research, 2007
- The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biologyImmunological Reviews, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II StudyAnnals of Surgical Oncology, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological SynapseImmunity, 2004
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995